Why Rare Disease Drugs Matter to Private Payers

Why Rare Disease Drugs Matter to Private Payers

May 4, 2021 1:00 PM to 2:00 PMOnline - Eastern Time
Area of Interest: Benefits Format: Web

Online Webinar hosted by CPBI Ontario

A recording of the session and a copy of the presentation are now available: for more information email [email protected]

There are already close to 100 drugs for rare diseases (DRDs) that consume almost 10% of all prescription drug spending. By definition these drugs cost at least $100,000 annually. Industry pooling is poorly structured to address the rapid growth in these important therapies which save or extend lives. A national strategy is being developed, but it is not clear what role and responsibility private drug plans should take, and who speaks for this very diverse group. This session will explore the impact of DRDs on private plans, risk mitigation, and how private payers might influence a national DRD policy.

Learning objectives:

- Define drugs for rare diseases (DRDs) and describe the current and trending impact on prescription drug spending
- Understand the need for DRDs, especially in oncology, and how to mitigate financial risk in private plans.
- Consider how private payer stakeholders can effectively participate in developing a national strategy
- Connect DRD policy and coverage to the broader debate about national pharmacare and its effects on the private payer community

Who should attend:

Insurers, benefit advisors, employers, pharmaceutical manufacturers, TPAs, pharmacy



Chris Bonnett, MHSc, PhD
Principal Consultant, H3 Consulting
Chris Bonnett established H3 Consulting in 1999, after 18 years of progressive experience in underwriting, reinsuring, selling, and marketing employee benefits. He provides practical prescription drug policy research for private and public drug plan leaders, and consults on workplace health strategy. He speaks and writes frequently on these topics.

Chris has been a volunteer director on the Boards of four health organizations. He is a sessional Professor in workplace health at Humber College, and is on the Advisory Board of the Sanofi Canada Healthcare Survey. He holds a Master's degree in Health Science from the University of Toronto, and a PhD in drug policy from the University of Waterloo.
For more information, please email: [email protected] or call 877 599 1414
CE Credits

CE credits will be offered in partnership through the Institute, Saskatchewan, Alberta and BC Insurance Councils, and Manitoba Insurance Council. A short quiz must be completed at the conclusion of the seminar to qualify for credit.
This CPBI online seminar complies with CEBS CPE policy guidelines: You may be interested to report the content of the present CPBI professional development activity and apply for CPE credit.

Webinar Recording

Please note that this session will be recorded and the recording will be available after the session.

Fees and Registration
Membership TypesRegular PricePlan Sponsor Price
Member$25.00 CDN$25.00 CDN
Plan Sponsor Individual Member$25.00 CDN$25.00 CDN
Associate Member$25.00 CDN$25.00 CDN
Student Membership$15.00 CDN -
Non Member$62.50 CDN$62.50 CDN
Cancellation Policy

Thank you to our 2021 Annual Program Partners for supporting CPBI Ontario

By continuing to use this website, you are agreeing to our use of cookies.